IP Library Granted Patent US 8,664,200
Granted Patent B2
US 8,664,200 · App. 12/586,650 · Granted Mar 4, 2014

Derivatives of 1-amino-2-cyclobutylethylboronic acid

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,664,200
App. No.
12/586,650
Granted
Mar 4, 2014
Kind
B2
Abstract

The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.

Claims (26)

1. A compound of formula (II):

or a pharmaceutically acceptable salt or boronic acid anhydride thereof, wherein:

P is R D —C(O)—;

R D is a substituted or unsubstituted mono- or bicyclic ring system selected from the group consisting of phenyl, pyridinyl, pyrimidinyl, pyrazinyl, naphthyl, benzimidazolyl, quinolinyl, isoquinolinyl, quinoxalinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, tetrahydroquinoxalinyl, and dihydrobenzoxazinyl;

each saturated ring carbon atom in R D is unsubstituted or is substituted with R d ;

each unsaturated ring carbon atom in R D is unsubstituted or is substituted with R d ;

each R d is -Q-R E ;

Q is —O—, —NH— or —CH 2 —;

R E is a substituted or unsubstituted aryl, heteroaryl, heterocyclyl or cycloaliphatic ring; and

Z 1 and Z 2 are each independently hydroxy, alkoxy, aryloxy, or aralkoxy: or Z 1 and Z 2 together form a moiety derived from a boronic acid complexing agent.

2. The compound of claim 1 , wherein R D is a phenyl, pyridinyl, pyrazinyl, or pyrimidinyl, which is substituted with a substituent of formula —O—R E , and R E is a substituted or unsubstituted phenyl, pyridinyl, pyrazinyl, or pyrimidinyl.

3. A pharmaceutical composition comprising a compound of claim l and a pharmaceutically acceptable carrier.

4. The compound of claim 1 wherein P is a R D —C(O)—; and R D is a substituted or unsubstituted phenyl, pyridinyl, pyrazinyl, or pyrimidinyl.

5. The compound of claim 1 , wherein R D is a substituted or unsubstituted pyrazinyl.

6. A compound which is:

or a pharmaceutically acceptable salt or boronic acid anhydride thereof.

7. The compound of claim 6 which is:

8. A compound which is:

or a pharmaceutically acceptable salt or boronic acid anhydride thereof.

9. The compound of claim 8 which is:

10. A compound which is:

or a pharmaceutically acceptable salt or boronic acid anhydride thereof.

11. The compound of claim 10 which is:

12. A compound which is:

or a pharmaceutically acceptable salt or boronic acid anhydride thereof.

13. The compound of claim 12 which is:

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 30, 2021
From: MILLENNIUM PHARMACEUTICALS, INC.
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 056729/0503 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 7, 2009
From: FLEMING, PAUL E.; LI, JING
To: MILLENNIUM PHARMACEUTICALS, INC.
Reel/Frame 023618/0033 →